TrialBMC pediatrics2018

DTwP-HB-Hib: antibody persistence after a primary series, immune response and safety after a booster dose in children 18-24 months old.

Hartono Gunardi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.